Bone densitometry developer CompuMed has received approval to market its OsteoGram system from the State Drug Administration of the People’s Republic of China. The product is a software system that utilizes hand x-ray image-processing technology to aid in the diagnosis of osteoporosis, monitor bone density change over time, and predict fracture risk.
CompuMed is touting OsteoGram as a cost-effective testing method for osteoporosis in areas where the capital acquisition costs of dual-energy x-ray absorptiometry (DEXA) scanners are prohibitive. There are approximately 129 million post-menopausal women in China who represent model candidates for the OsteoGram test, according to the firm.
By AuntMinnie.com staff writersJune 25, 2002
Related Reading
CompuMed revenues edge higher in Q2, May 15, 2002
CompuMed hires new management team, May 13, 2002
CompuMed revenues dip, February 14, 2002
CompuMed eyes international markets, February 6, 2002
Copyright © 2002 AuntMinnie.com
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
